Article Sidebar

pdf
Date Published: 30/08/2023
Abstract Views: 143
Views pdf: 100
DOI: https://doi.org/10.51298/vmj.v529i1B.6407
Issue
Vol. 529 No. 1B (2023)
Section
Các bài báo
How to Cite
Trịnh, L. H., Trần, Đình A., & Đỗ, A. T. (2023). THE RESULT OF ADJUVANT VINORELBINE PLUS CISPLATIN IN COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER AT HANOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 529(1B). https://doi.org/10.51298/vmj.v529i1B.6407

THE RESULT OF ADJUVANT VINORELBINE PLUS CISPLATIN IN COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER AT HANOI MEDICAL UNIVERSITY HOSPITAL

Lê Huy Trịnh1,, Đình Anh Trần2, Anh Tú Đỗ3
1 HMU
2 Hanoi Medical University Hospital
3 K hospital

Main Article Content

Abstract

Objectives: Evaluating the result of adjuvant vinorelbine plus cisplatin in completely resected stage IB-IIIA NSCLC. Patients and methods: Descriptive study of 73 patients completely resected stage IB-IIIA non-small cell lung cancer were received adjuvant vinorelbine plus cisplatin chemotherapy at Hanoi Medical University Hospital from 01/2016 to 4/2022. Results: The mean age of 57,14 years old, male: female ratio was 2,85:1. 24 (32,9%) patients had postoperative stage IB disease, 25 (34.2%) had stage IIA disease, 14 (19,2%) had stage IIB disease and 10 (13,7%) had stage IIIA disease. The major histological type was adenocarcinoma (78.1%). Median disease free survival was 29,30 ± 1,63 months, and 3-year survival was 41,1%. Chemotherapy caused hematologic side effects in 66,67% of patients including neutropenia in 61,4% and grade 3/4 neutropenia in 27.4%. Non-hematologic toxic effects of chemotherapy were reported at low rates and almost mild (grade 1/2). Conclusions: The vinorelbine-cisplatin regimen is an effective regimen in the adjuvant treatment of non-small cell lung cancer, the study showed that the results in disease-free survival and overall survival were comparable to those of other studies in the world. The most common side effect was neutropenia, the other side effects were reported at low rate and usually mild.

Article Details

Keywords

Non-small cell lung cancer, vinorelbine, cisplatin, adjuvant chemotherapy

References

1. Sung, H., Ferlay, J., Siegel, R. L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians.2021; 71(3): 209-249.
2. Trần Văn Thuấn (2019). Non-small cell lung cancer. Guidelines for the diagnosis and treatment of common cancers. Medical Publishing House, Hanoi, 92–105.
3. Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai (2010). Lung cancer. Medical treatment of cancer. Medical Publishing House, Hanoi, 81–98.
4. Lê Văn Quảng, Trịnh Lê Huy (2021). Chemotherapy for Cancer, Medical Publishing House, Hanoi, 207-221.
5. Douillard J.-Y., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9): 719–727.
6. Pepe C., Hasan B., Winton T.L. et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol. 2007; 25(12): 1553–1561.
7. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med. 2005; 352(25): 2589–2597.
8. Douillard J.-Y., Tribodet H., Aubert D. et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol. 2010; 5(2): 220–228.
9. Shukuya T., Takahashi T., Tamiya A. et al. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study. Jpn J Clin Oncol. 2009; 39(3): 158–162.
10. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med. 2005;352(25): 2589–2597.